A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

LEO Pharma66 enrolled

Overview

This is a phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of 4 different oral formulations of LEO 32731 in healthy subjects. The trial will be conducted in 3 parts at a single site. Each eligible subject will be enrolled into 1 group only and will participate in 3 treatment periods.

Part 1 will evaluate the pharmacokinetics of single doses of 4 test formulations of LEO 32731 compared with a reference formulation. Part 2 will evaluate the effect of food on the pharmacokinetics of selected test formulations of LEO 32731. Part 3 will evaluate the tolerability and safety of selected test formulations of LEO 32731 after multiple dosing. Based on data from Part 1, up to 3 formulations will be taken forward to Part 2. If none of the formulations are considered appropriate to take forward to Part 2, the trial will stop after Part 1. Similarly, based on data from Part 2, up to 2 formulations will be taken forward to Part 3. If none of the formulations are considered appropriate to take forward to Part 3, the trial will stop after Part 2.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Healthy

Interventions

LEO 32731 modified release tabletDRUG

At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.

LEO 32731 blend, hard capsuleDRUG

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

LEO 32731 API, hard capsuleDRUG

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key inclusion criteria: * Age 18 to 65 years, inclusive. * Body mass index of 18.5 to 29.9 kg/m2, inclusive. * In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment (specifically, blood pressure must be within normal reference range), 12-lead ECG, clinical laboratory evaluations, aspartate aminotransferase and alanine aminotransferase not above the upper limit of normal (Gilbert's syndrome is not acceptable). * Female subjects of childbearing potential must be willing to use a highly effective form of birth control in conjunction with a barrier method of contraception throughout the trial and for at least 90 days after final follow-up. * Male subjects with a female partner of childbearing potential must be willing to use a highly effective form of birth control in conjunction with male barrier method of contraception (i.e. male condom with spermicide) throughout the trial and for at least 90 days after final follow-up. Key exclusion criteria: * Systemic or topical treatment within 14 days prior to first dose administration unless in the opinion of the investigator the medication will not interfere with the trial procedures or compromise safety. * Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to first dose administration. * Subjects who smoke more than an average of 10 cigarettes per day. * History of chronic alcohol or drug abuse within 12 months prior to screening. * Subjects with ≥3 bowel movements per day. * Any disorder which is not stable and could: Affect the safety of the subject throughout the trial; Influence the findings of the trial; Impede the subject's ability to complete the trial. Examples include but are not limited to cardiovascular, GI, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders and major physical impairment.

Locations (1)

LEO Pharma Investigational Site

Leeds, United Kingdom

Outcomes

Primary Outcomes

Part 1. AUC0-∞

AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 1. Relative bioavailability (F-rel)

F-rel: AUC0 ∞ test formulations/AUC0-∞ reference formulation (derived from the statistical analysis of AUC0-∞)

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 1. C-max

C-max: Maximum observed plasma concentration

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 1. t-max

t-max: Time to reach maximum observed plasma concentration

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 2. AUC0-∞

AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

Part 2. Relative bioavailability (F-rel)

F-rel: AUC0 ∞ test formulations/AUC0-∞ reference formulation (derived from the statistical analysis of AUC0-∞)

Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

Part 2. C-max

C-max: Maximum observed plasma concentration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Part 1. Number of GI-related AEs and number of subjects with GI-related AEs during each combination of treatment and period.

AEs: adverse events; GI: gastrointestinal

Time frame: 24 days (from first dose in first treatment period until end of last treatment period) in Part 1

Part 1. Number of total AEs and number of subjects with AEs during each combination of treatment and period

AEs: adverse events

Time frame: 24 days (from first dose in first treatment period until end of last treatment period) in Part 1

Part 1. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

Part 1. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

Part 1. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

Part 1. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

Part 1. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

Part 1. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

Part 1. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

QTcF: QT interval corrected for heart rate according to Fridericia's method. Normal: ≤450 msec for males and ≤470 msec for females. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

Part 1. AUC0-t

AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 1. t1/2

t1/2: apparent terminal half-life

Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

Part 2. Number of GI-related AEs and number of subjects with GI-related AEs during each combination of treatment and period.

AEs: adverse events; GI: gastrointestinal

Time frame: 28 days (from first dose in first treatment period until end of last treatment period) in Part 2

Part 2. Number of total AEs and number of subjects with AEs during each combination of treatment and period

AEs: adverse events

Time frame: 28 days (from first dose in first treatment period until end of last treatment period) in Part 2

Part 2. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

Part 2. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

Part 2. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

Part 2. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

Part 2. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

Part 2. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

Part 2. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

Part 2. AUC0-t

AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

Part 2. t1/2

t1/2: apparent terminal half-life

Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

Part 3. AUC0-∞

AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

Part 3. C-max

C-max: Maximum observed plasma concentration

Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

Part 3. t-max

t-max: Time to reach maximum observed plasma concentration

Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

Part 3. AUC0-t

AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

Part 3. t1/2

t1/2: apparent terminal half-life

Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

Part 3. Number of total AEs and number of subjects with AEs during the treatment period

AEs: adverse events

Time frame: From Day 1 (first dose) to Day 19 (end of treatment period) in Part 3

Part 3. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during the treatment period in Part 3: Days 1, 3, 5, 7, 9, and 11: predose and 4 hours postdose; Day 17: predose, 4 hours, and 12 hours postdose; Day 19 (=48 hours postdose)

Part 3. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

Part 3. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

Part 3. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

Part 3. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)

Part 3. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)

Part 3. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)